Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Urogen Pharma will report Q1 2026 results before the market opens on Wednesday, May 6, with analysts projecting a loss of ($0.4824) EPS and revenue of $44.83 million.
• The stock recently traded near $23 (down 3.5%), has a market cap of $1.12 billion and a 12‑month range of $3.42–$30.00; Wall Street consensus is a “Moderate Buy” with an average price target of $34.13, amid mixed analyst ratings.
• Insiders (including the general counsel) sold shares in February, bringing insider ownership to about 4.7%, while institutional investors hold roughly 91.3% of the company.

Urogen Pharma (NASDAQ:URGN - Get Free Report) is projected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Urogen Pharma to post earnings of ($0.4824) per share and revenue of $44.8280 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.12. The company had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Urogen Pharma Trading Down 3.5%

Shares of NASDAQ:URGN opened at $23.00 on Friday. The stock has a fifty day simple moving average of $20.32 and a two-hundred day simple moving average of $21.33. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $30.00. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -7.19 and a beta of 1.58.

Wall Street Analyst Weigh In

URGN has been the subject of several recent analyst reports. Jefferies Financial Group raised Urogen Pharma to a "strong-buy" rating in a research report on Friday, April 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research report on Monday, April 20th. Oppenheimer restated an "outperform" rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Finally, D. Boral Capital reiterated a "buy" rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $34.13.

Insider Buying and Selling at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,479 shares of the company's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company's stock, valued at $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares in the company, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is owned by insiders.

Institutional Trading of Urogen Pharma

A number of institutional investors have recently made changes to their positions in URGN. Franklin Resources Inc. bought a new position in Urogen Pharma during the fourth quarter valued at approximately $392,000. Cetera Investment Advisers purchased a new stake in Urogen Pharma in the second quarter worth approximately $361,000. Main Street Financial Solutions LLC grew its position in Urogen Pharma by 8.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after purchasing an additional 1,968 shares during the period. WINTON GROUP Ltd purchased a new stake in Urogen Pharma during the 4th quarter valued at $309,000. Finally, Quantinno Capital Management LP purchased a new stake in Urogen Pharma during the 2nd quarter valued at $289,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.